Randomised trial of paclitaxel versus doxorubicin as first-line chemotherapy for advanced breast cancer: quality of life evaluation using the EORTC QLQ-C30 and the Rotterdam Symptom Checklist

Section: Discussionmentioning

confidence: 99%

Quality of life in women with metastatic breast cancer during 9 months after randomization in the TEX trial (epirubicin and paclitaxel w/o capecitabine)

Svensson

Einbeigi

Johansson

et al. 2010

“…Available QOL measures tend to focus on the last week before the next cycle of IV chemotherapy and, therefore, may not actually pick up effects of an IV treatment since the measure is normally applied at the beginning of a clinic visit before any test or intervention has been administered. Quality-of-life outcomes can potentially also be used as a prognostic factor to predict survival of breast cancer patients [29]; thus, it is vitally important to consider potential negative effects of treatment on QOL. The addition of lapatinib to capecitabine significantly increases TTP without evidence of a deleterious effect on patients' QOL, confirming its clinical benefit to patients with advanced HER2-positive breast cancer that has progressed on trastuzumab therapy.…”

Section: Discussionmentioning

confidence: 99%

Lapatinib plus capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: quality-of-life assessment

Zhou

Cella

Cameron

et al. 2009

The randomized phase III trial EGF100151 demonstrated that the combination of lapatinib plus capecitabine (L + C) significantly improved time to progression (TTP) compared with capecitabine alone (C) in heavily pretreated patients with HER2+ (ErbB2+) advanced or metastatic breast cancer. This analysis assessed the effects of study treatments on quality of life (QOL) among patients in EGF100151. Quality of life was assessed using the Functional Assessment of Cancer Therapy-Breast (FACT-B) and EuroQoL (EQ-5D) questionnaires. Patients completed questionnaires during efficacy and safety assessment visits (i.e., at screening visit, every 6 weeks for the first 24 weeks, every 12 weeks thereafter, and at discontinuation of study treatment). Primary analyses compared the treatment groups based on change from baseline QOL. Exploratory analyses compared proportion of patients achieving minimum important differences (MID) in QOL scores and the relationship between QOL and tumor status. Quality of life for patients in both treatment groups was maintained during 24 weeks of follow-up. Adjusted mean changes from baseline in all QOL scores for the L + C arm were comparable to those for the C arm. The between-group differences ranged from 0.7 to 2.2 (FACT-B total) and 0.3 to 1.8 (EQ-5D visual analog scale) and were consistently in favor of the L + C arm, although not statistically significant. Patients with an objective tumor response or stable disease showed clinically meaningful differences in QOL scores compared to patients with progressive disease. A greater proportion of patients receiving L + C versus C achieved the MID for all five QOL scores, although differences were not statistically significant. The addition of lapatinib to capecitabine significantly increases TTP without any evidence of a deleterious effect on patients' QOL, confirming its clinical benefit in this heavily pretreated patient population with advanced HER2+ breast cancer that has progressed on trastuzumab therapy.

“…The compliance with QoL assessment compares favorably with other large trials of first-line chemotherapy for metastatic breast cancer [4,6,17,18]. Despite relatively high-compliance rates, we could not show any significant difference in overall (QLQ-C30 items 29-30) between doxorubicin-docetaxel and doxorubicin-paclitaxel combinations.…”

Section: Discussionmentioning

confidence: 47%

A phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study

Cassier

Chabaud

Trillet‐Lenoir

et al. 2007